Sugi Predict

Sugi Predict / Compounds / SCHEMBL485156

SCHEMBL485156

SCHEMBL485156

COC(=O)C1CCN(C(=O)OCc2ccccc2)CC1

nearest known ligand 0.75

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ SMN1; SMN2 Q16637 4/20 0.75
▸ NPC1 O15118 4/20 0.75
▸ RAB9A P51151 4/20 0.75
▸ CYP2C19 P33261 1/20 0.71
▸ HTT P42858 1/20 0.70
▸ ALDH1A1 P00352 3/20 0.58
▸ NPSR1 Q6W5P4 2/20 0.57
▸ MAPT P10636 1/20 0.57
▸ HPGD P15428 1/20 0.57
▸ HSD17B10 Q99714 1/20 0.57
▸ ENPP2 Q13822 1/20 0.57
▸ GRIN2B Q13224 7/20 0.57
▸ MEN1 O00255 2/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ CYP2D6 P10635 4/20 0.56
▸ CYP2C9 P11712 4/20 0.56
▸ CYP3A4 P08684 3/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31170142 0.95 SMN1; SMN2 (0.69) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL31170470 0.95 SMN1; SMN2 (0.69) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL31170255 0.95 SMN1; SMN2 (0.69) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL27358982 0.93 SMN1; SMN2 (0.66) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL14348062 0.92 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL631512 0.92 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL16025051 0.92 SMN1; SMN2 (0.68) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL31586614 0.90 SMN1; SMN2 (0.63) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL630697 0.88 SMN1; SMN2 (0.73) SMN1; SMN2NPC1RAB9ACYP2C19HTT
SCHEMBL30851742 0.87 SMN1; SMN2 (0.72) SMN1; SMN2NPC1RAB9ACYP2C19HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 77 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113976072-B Preparation device and method of 4-formyl-N-CBZ piperidine 武汉青风凯默生物医药科技有限公司 2024-02-23 — — CN claimed
CN-113976072-A Preparation device and method of 4-formyl-N-CBZ piperidine 武汉青风凯默生物医药科技有限公司 2022-01-28 — — CN claimed
CN-113227103-B Trisubstituted heteroaryl derivatives as SRC homo-2 phosphatase inhibitors 尼坎治疗公司 2024-10-01 — — CN disclosed
US-20240174696-A1 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS GENENTECH, INC. (US) 2024-05-30 — — US disclosed
EP-4347594-A1 2, 8-DIAZASPIRO [4.5] DECANE COMPOUNDS Genentech, Inc. (US) 2024-04-10 — — EP disclosed
WO-2024054919-A1 SPIRO-LACTAM NMDA RECEPTOR MODULATORS AND USES THEREOF TENACIA BIOTECHNOLOGY (HONG KONG) CO., LIMITED (CN) 2024-03-14 — — WO disclosed
CN-113976072-B Preparation device and method of 4-formyl-N-CBZ piperidine 武汉青风凯默生物医药科技有限公司 2024-02-23 — — CN disclosed
CN-117425654-A 2, 8-diazaspiro [4.5] decane compounds 基因泰克公司 2024-01-19 — — CN disclosed
US-20230416262-A1 TRPML MODULATORS CASMA THERAPEUTICS, INC. 2023-12-28 — — US disclosed
EP-4192957-A2 TRPML MODULATORS Casma Therapeutics, Inc. (US) 2023-06-14 — — EP disclosed
CN-116113698-A TRPML modulators 卡斯玛治疗公司 2023-05-12 — — CN disclosed
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS EFREMOV IVAN 2008-11-13 — — US disclosed
EP-1957494-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME Incyte Corporation (US) 2008-08-20 — — EP disclosed
WO-2007117559-A2 RENIN INHIBITORS VITAE PHARMACEUTICALS, INC. (US) 2007-10-18 — — WO disclosed
WO-2007067504-A2 LACTAM COMPOUNDS AND METHODS OF USING THE SAME INCYTE CORPORATION (US) 2007-06-14 — — WO disclosed
US-20070129345-A1 Lactam compounds and methods of using the same INCYTE CORPORATION 2007-06-07 — — US disclosed
US-6887889-B2 Aryl and biaryl piperdines with MCH modulatory activity PHARMACOPEIA DRUG DISCOVERY, INC. (US) 2005-05-03 — — US disclosed
EP-1377293-A1 ARYL AND BIARYL PIPERIDINES USED AS MCH ANTAGONISTS PHARMACOPEIA, INC. (US) 2004-01-07 — — EP disclosed
US-20030013720-A1 Aryl and biaryl piperidines with MCH modulatory activity PHARMACOPEIA, INC. 2003-01-16 — — US disclosed
WO-2002083134-A1 ARYL AND BIARYL PIPERIDINES USED AS MCH ANTAGONISTS PHARMACOPEIA, INC. (US) 2002-10-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030013720-A1 Aryl and biaryl piperidines with MCH modulatory activity MCHR1, MCHR2, MC5R SMN1; SMN2 490/4885NPC1 429/4885RAB9A 2249/4885
US-20080280933-A1 BENZIMIDAZOLYL COMPOUNDS PAICS, TMBIM6, ABCG2 SMN1; SMN2 478/4885NPC1 282/4885RAB9A 1014/4885
US-20240174696-A1 2,8-DIAZASPIRO[4.5]DECANE COMPOUNDS LATS1, LATS2, GLS2 SMN1; SMN2 3384/4885NPC1 2463/4885RAB9A 2510/4885
US-20070129345-A1 Lactam compounds and methods of using the same HSD11B1, HSD17B11, HSD17B1 SMN1; SMN2 2604/4885NPC1 460/4885RAB9A 2852/4885
US-20230416262-A1 TRPML MODULATORS TRPM2, TRPM4, TRPM5 SMN1; SMN2 1776/4885NPC1 346/4885RAB9A 2068/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.